ideasIdea
Test protein and resistance training during immunotherapy
Muscle is an immune organ as well as a movement organ. Building it during immunotherapy might improve how well the treatment works, not just how patients feel.
Muscle secretes myokines including interleukin-15 and irisin that affect immune cell function, and low muscle mass is associated with poorer checkpoint inhibitor outcomes in several retrospective series. Whether that association is causal or simply reflects disease burden is unknown, and a randomised exercise and protein intervention during checkpoint therapy would answer it while also improving function.
Hypothesis
Supervised resistance training with protein supplementation during checkpoint blockade improves progression-free survival or response rate compared with usual care, mediated by measurable changes in circulating immune cell phenotype.
Rationale
Exercise increases natural killer cell mobilisation and alters myeloid phenotype in humans, and mouse studies show exercise-dependent improvements in tumour immune control. The intervention has no toxicity and independent quality-of-life benefit, so the trial is low-risk.
What would test it
A randomised trial in patients starting checkpoint blockade with response and immune profiling co-primary endpoints, powered pragmatically and embedded in routine care.
Maturity
speculative
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- Cachexia, toxicity and the limits of the patient · Patients often die of wasting or cannot tolerate the doses that would work. Treating the patient, not just the tumour, lags far behind.
- No one can predict who responds to immunotherapy · Checkpoint drugs cure some patients and do nothing for most. We still cannot tell the two apart before treating.
- Cold tumours and the immunosuppressive microenvironment · Most tumours keep the immune system out or asleep, so immunotherapy helps only a minority.